Safety and Effectiveness of 100 mg/kg/day Deferiprone in Patients with Thalassemia Major

LAUR Repository

Show simple item record

dc.contributor.author Taher, A.
dc.contributor.author Sheikh-Taha, M.
dc.contributor.author Sharara, A.
dc.contributor.author Inati, A.
dc.contributor.author Koussa, S.
dc.contributor.author Dhillon, A.P.
dc.contributor.author Hoffbrand, A.V. en_US
dc.date.accessioned 2016-06-01T12:49:40Z
dc.date.available 2016-06-01T12:49:40Z
dc.date.copyright 2005 en_US
dc.date.issued 2016-06-01
dc.identifier.issn 0001-5792 en_US
dc.identifier.uri http://hdl.handle.net/10725/3922
dc.description.abstract Deferiprone at a dose of 75 mg/kg/day is not sufficiently effective to maintain iron stores at a level which has been considered safe in all patients with iron overload. Our main aim was to determine the safety of long-term therapy with high-dose (100 mg/kg/day) deferiprone. A secondary aim was to determine the efficacy of this high dose. Twelve thalassemia major patients received deferiprone at a dose of100 mg/kg/day over 2 years. Transient aspartate aminotransferase increase (8 patients), gastrointestinal discomfort (3 patients) and arthralgia (2 patients) were the most commonly reported side effects. None of the patients discontinued therapy. The mean serum ferritin level fell from 3,901 ± 3,618 to 1,790 ± 2,205 µg/l after 2 years (p < 0.05). Five of the 12 patients continued to receive deferiprone for an additional 3 years. No new side effects were encountered. The mean serum ferritin level in this subgroup was initially 2,510 ± 332 µg/l and dropped to 1,511 ± 664 µg/l after 5 years (p < 0.05). Liver iron levels at the end of the 2-year study ranged from 1.0 to 30.9 mg/g dry weight, 3 of the patients having levels above 15 mg/g. en_US
dc.language.iso en en_US
dc.title Safety and Effectiveness of 100 mg/kg/day Deferiprone in Patients with Thalassemia Major en_US
dc.type Article en_US
dc.description.version Published en_US
dc.title.subtitle A Two-Year Study en_US
dc.author.school SOP en_US
dc.author.idnumber 199410150 en_US
dc.author.department Pharmacy Practice Department en_US
dc.description.embargo N/A en_US
dc.relation.journal Acta Haematologica en_US
dc.journal.volume 114 en_US
dc.journal.issue 3 en_US
dc.article.pages 146-149 en_US
dc.identifier.doi http://dx.doi.org/10.1159/000087888 en_US
dc.identifier.ctation Taher, A., Sheikh-Taha, M., Sharara, A., Inati, A., Koussa, S., Ellis, G., ... & Hoffbrand, A. V. (2005). Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study. Acta haematologica, 114(3), 146-149. en_US
dc.author.email marwan.taha@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php en_US
dc.identifier.url http://www.karger.com/Article/Abstract/87888 en_US
dc.orcid.id https://orcid.org/0000-0002-8037-1201 en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account